DK155732B - ANALOGY PROCEDURE FOR THE PREPARATION OF AMINO ACID DERIVATIVES - Google Patents
ANALOGY PROCEDURE FOR THE PREPARATION OF AMINO ACID DERIVATIVES Download PDFInfo
- Publication number
- DK155732B DK155732B DK442477AA DK442477A DK155732B DK 155732 B DK155732 B DK 155732B DK 442477A A DK442477A A DK 442477AA DK 442477 A DK442477 A DK 442477A DK 155732 B DK155732 B DK 155732B
- Authority
- DK
- Denmark
- Prior art keywords
- effect
- compound
- general formula
- optically active
- vitamin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 18
- 150000003862 amino acid derivatives Chemical class 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 22
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 claims description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229960003080 taurine Drugs 0.000 claims description 5
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims description 4
- SUZRRICLUFMAQD-UHFFFAOYSA-N N-Methyltaurine Chemical compound CNCCS(O)(=O)=O SUZRRICLUFMAQD-UHFFFAOYSA-N 0.000 claims description 4
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- -1 p-nitrophenoxy, pentachlorophenoxy Chemical group 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 description 35
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 19
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 19
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 19
- 235000019155 vitamin A Nutrition 0.000 description 19
- 239000011719 vitamin A Substances 0.000 description 19
- 229940045997 vitamin a Drugs 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 8
- 229910052710 silicon Inorganic materials 0.000 description 8
- 239000010703 silicon Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- 206010018691 Granuloma Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229960002989 glutamic acid Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- SFLHIOGTRJZPOD-YFKPBYRVSA-N (2S)-2-amino-4-[methyl(2-sulfoethyl)amino]-4-oxobutanoic acid Chemical compound N[C@@H](CC(=O)N(CCS(=O)(=O)O)C)C(=O)O SFLHIOGTRJZPOD-YFKPBYRVSA-N 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- DTAFLBZLAZYRDX-UHFFFAOYSA-N OOOOOO Chemical compound OOOOOO DTAFLBZLAZYRDX-UHFFFAOYSA-N 0.000 description 2
- 241000499504 Rana dalmatina Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 125000003164 beta-aspartyl group Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 208000000381 Familial Hypophosphatemia Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010020914 Hypervitaminoses Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 208000001393 Lathyrism Diseases 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010048979 Sinobronchitis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010042606 Tyrosine transaminase Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008359 toxicosis Effects 0.000 description 1
- 230000018889 transepithelial transport Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 150000002266 vitamin A derivatives Chemical class 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Birds (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
DK 155732BDK 155732B
Den foreliggende opfindelse angår en analogifremgangsmåde til fremstilling af hidtil ukendte aminosyre-derivater med den almene formel R1-NH-CH-CO-A1The present invention relates to an analogous process for the preparation of novel amino acid derivatives of the general formula R1-NH-CH-CO-A1
5 I5 I
(CHo) I(CHo) I
I 2 η 1I 2 η 1
CO-N-CH-(CH0 ) -BCO-N-CH- (CHO) -B
I '2 2 tI '2 2 t
R RR R
11 12 hvor A , B , R, R , R , n og t har de i krav 1 1 s indled-10 ning angivne betydninger, eller fysiologisk acceptable salte eller optisk aktive antipoder deraf.11, wherein A, B, R, R, R, n and t have the meanings specified in the preamble of claim 1, or physiologically acceptable salts or optically active antipodes thereof.
Disse forbindelser har værdifulde biologiske eller farmakologiske virkninger.These compounds have valuable biological or pharmacological effects.
Blandt de ifølge opfindelsen fremstillede forbin-15 delser skal på grund af dens biologiske virkning navnlig fremhæves γ-L-glutamyltaurin, der har formlen H„N-CH-COOH Å I CH„ I ÅAmong the compounds of the invention, due to its biological action, it is particularly noted that γ-L-glutamyltaurine having the formula H₂N-CH-COOH
CH2 XXIVCH2 XXIV
20 C0-NH-CH2-CH2-S020HC0-NH-CH2-CH2-SO20H
og som har et bredt terapeutisk og præventivt virkningsspektrum over for sygelige forandringer der kan føres tilbage til beskadigelser af "AGAS" (det aerobiosfæri-25 ske genetiske adaptionssystem).and which has a broad therapeutic and preventive spectrum of action against morbid changes that can be traced back to damage by "AGAS" (the aerobiospheric genetic adaptation system).
Til belysning af begrebet "AGAS" opregnes i det følgende de vigtigste væv og organer der danner dette system.To illustrate the concept of "AGAS", the following are the main tissues and organs that form this system.
a) Alle biologiske grænseflader der står i berø-30 ring med den ydre luft som biosfæren (hud og huddannelser, øjets hornhinde og Conjunktiva, mund- og svælghulrum, luftveje og lunge); b) skelet og led (rørknogler og svampeagtige knogler, kugleled, synoviale membraner, skeletmuskulatur); 35 c) de til reguleringen af ionhusholdningen delta gende organer (transepiteliske transporsystem: tarmtrævler og nyrekanal); 2(a) All biological interfaces that are in contact with the external air such as the biosphere (skin and skin formation, corneal and conjunctival eyes, oral and pharyngeal cavities, respiratory tract and lung); b) skeleton and joints (tubular and spongy bones, ball joints, synovial membranes, skeletal muscle); C) the organs involved in the regulation of the ionic household (transepithelial transport system: intestinal tracts and renal duct); 2
DK 155732BDK 155732B
d) det til findeling af næringen nødvendige teko-donte (i tandaveolerne med rødder fastgjorte) tandsæt; e) høre-, lugte- og stemmeorganer.d) the tooth kit needed for comminuting the food (rooted in tandaveolans); (e) hearing, smell and voice organs.
De omhandlede forbindelser udøver således en gun-5 stig biologisk eller terapeutisk virkning på de her opregnede organer eller væv af AGAS-systemet.Thus, the compounds of this invention exert a favorable biological or therapeutic effect on the organs or tissues of the AGAS system enumerated herein.
De ved fremgangsmåden ifølge opfindelsen fremstillede forbindelser virker desuden på følgende funktioner der står i sammenhæng med AGAS-systemet: strålingsbe-10 skyttelse, begunstigelse af sårheling, almindelig aktiverende virkning på mesenkym, beskyttelse mod den stadigt voksende infektions- og tilsmudsningsfare hos hud og slimhinder (den fugtige slimhindes lysozymproduktion, aktivering af fimreepiteler i luftvejene), forøget beskyt-15 telse mod de af vira og svampe forårsagede infektioner.In addition, the compounds of the present invention act upon the following functions associated with the AGAS system: radiation protection, favoring wound healing, common activating effect on mesenchyme, protection against the ever-growing infection and contamination risk of skin and mucosa ( the lysozyme production of the moist mucosa, activation of the gut epithelium in the respiratory tract), increased protection against the infections caused by viruses and fungi.
De ved fremgangsmåden ifølge opfindelsen fremstillede forbindelser er virksomme mod de stadigt og i høj grad stigende stress-virkninger der er knyttet til livet på fastlandet (fx meteorologisk indflydelse, store 20 forskelle mellem dag- og nattemperatur, forhøjet fare for kvæstelser), idet de stabiliserer adaptionssyndromet og samtidigt afværger glukokortikoidernes perifere vævsskader (som fx skader i bindevævet, kvæstelser af knoglema-trix-bestanddele). Udvikling af immunhomøostase (stigende 25 erkendelsesevne hos legemet om hvilke celler der er kropsegne og hvilke der ikke er).The compounds of the present invention are effective against the ever-increasing stress effects associated with mainland life (e.g., meteorological influence, large differences in day and night temperature, increased risk of injury) as they stabilize. adaptation syndrome and at the same time mitigates the peripheral tissue damage of glucocorticoids (such as damage to the connective tissue, injury to bone-trix constituents). Development of immuno-homeostasis (increasing body recognition of which cells are suitable and which are not).
De ved fremgangsmåden ifølge opfindelsen fremstillede forbindelser udøver deres virkning dels umiddelbart, dels over reguleringen af vitamin A metabolismen, 30 ved produktion af vitamin A metaboliter med stærkere polær karakter. Denne virkning kan sammenlignes med parathormonets virkning på 25-hydroxycholecalciferol-1oclhy-droxylase-enzymet i nyrekanalen. Virkningsretningerne af forbindelserne er følgende: 35 3The compounds prepared by the process of the invention exert their effect, both immediately and partly through the regulation of vitamin A metabolism, in the production of vitamin A metabolites of a stronger polar nature. This effect is comparable to the effect of the parathormone on the 25-hydroxycholecalciferol-1oclhydroxylase enzyme in the renal tract. The directions of action of the compounds are as follows:
DK 155732BDK 155732B
Δ) Virkninger med vitamin A-karakterer: a) Farmakologiske og biokemiske virkninger:Δ) Vitamin A grade effects: a) Pharmacological and biochemical effects:
Forøgende virkning på kondroitinsulfatsyntese; gunstig virkning på sårhelingen eller på den ved indgift af kortison eksperi- 5 mentelt forringede sårheling hos rotter og hunde; potenserende virkning på vitamin A's virkning hos rotter og høns ved eksperimentelt fremkaldte hypo- eller hypervitaminoser; dæmpende virkning på de ulcerations-betingede stress-virkninger hos rotter; begunstigende virkning på degranulationen af mastocyter; forøgende virkning på 10 produktionen af lysozym; virkning på sporstofhusholdningen (silicium, zink, kobber, mangan, fluor); fremmende virkning på epiteldannelsen; fremmende virkning på den alkaliske fosfataseaktivi-tet; virkning på den ved lokal indvirkning af vitamin A fremkaldte granulomposedannelse (Granulomsackbildung); det yderst flade for-15 løb af dosis-virkningskurven eller ændringen af virkningens fortegn ved store doser; aktiverende virkning på Golgi-apparatet; begunstigende virkning på dannelsen af slim- eller bægerceller; forøgende virkning på koncentrationen af vitamin A.Increasing effect on chondroitin sulfate synthesis; beneficial effect on the wound healing or on the experimentally impaired wound healing in rats and dogs by cortisone administration; potentiating effect on the effect of vitamin A in rats and chickens in experimentally induced hypo- or hypervitaminoses; attenuating effect on the ulceration-related stress effects in rats; beneficial effect on the degranulation of mastocytes; increasing effect on the production of lysozyme; effect on household traceability (silicon, zinc, copper, manganese, fluorine); promoting effect on epithelial formation; promoting effect on the alkaline phosphatase activity; effect on the granuloma bag formation (Granulomsackbildung) induced by local action of vitamin A; the extremely flat course of the dose-effect curve or the change of effect sign at large doses; activating effect on the Golgi apparatus; beneficial effect on the formation of mucus or goblet cells; increasing effect on the concentration of vitamin A.
20 b) Klinisk-terapeutiske indikationer: keratokonjunktivis sicca; Sjogrens syndrom; rhino-laryngo-pharingitis sicca; ozæna; kronisk bronchitis; sinobronchitis; mucoviscidose; konstitutionelle lungesygdomme hos småbørn; paradentose; hudens og slimhindernes smittetilbøjelighed for vira og svampe; kortison-antagonistisk 25 virkning; gunstig virkning på helingen ved operationssår og slimhindesår; erosio colli; pruritusagtige lidelser; nedsættelse af lugte- og smagssansen.B) Clinical-therapeutic indications: keratoconjunctivis sicca; Sjogren's syndrome; rhino-laryngo-pharingitis sicca; ozæna; chronic bronchitis; sinobronchitis; mucoviscidosis; constitutional lung disease in young children; periodontal disease; skin and mucosal susceptibility to viruses and fungi; cortisone antagonistic action; beneficial effect on healing of operative and mucosal wounds; erosio colli; pruritus-like disorders; reducing the sense of smell and taste.
30 B) Virkninger uden vitamin A-karakter a) Farmakologiske og biokemiske virkninger: virkning på blodsukkerniveauet med hensyn til en forbigående sænkning; forøgende virkning på fosfaturi, sænkende virkning på fosfatniveauet t 35 i serum; strålingsbeskyttende virkning; formindskende virkning på 430 B) Vitamin A-grade effects (a) Pharmacological and biochemical effects: effects on blood glucose levels with a transient decrease; increasing effect on phosphaturia, lowering effect on phosphate level t 35 in serum; radiation protective effect; diminishing effect on 4
DK 155732BDK 155732B
den nødvendige tid der går med at nå målet ved labyrintforsøg hos inaktiverede dyr; formindskende virkning på eksperimentelt fremkaldte fluor- og kadmiumtoxikoser; forøgende virkning på den cykliske adenosinmonofosfat-udtømning af nyrerne; dæmpende virkning 5 på symptomerne ved eksperimentelt fremkaldt lathyrismus; formindskelse af histaminfølsomheden; forøgende virkning på aktiviteten af leverenzymet tyrosinaminotransferase.the time needed to reach the goal of maze trials in inactivated animals; diminishing effect on experimentally induced fluorine and cadmium toxicosis; increasing effect on the cyclic adenosine monophosphate depletion of the kidneys; attenuating effect 5 on the symptoms of experimentally induced lathyrism; decrease in histamine sensitivity; enhancing effect on liver enzyme tyrosine aminotransferase activity.
b) Terapeutiske indikationer: svage bestrålingsskader; vitiligo; muskelhypotoni; psykoenergetiserende virkning; gunstig 10 virkning på involutionelle og gerontologiske tilstande samt på de mnestiske funktioner; keloide tilbøjeligheder; spondylosis ankylo-poetica; sygdomme hos bevægelsesorganerne på grund af slid; scle-rotisk fundus; amyloidose; morphæa; fibrocytisk mastopati.b) Therapeutic indications: weak radiation damage; vitiligo; muscle hypotonia; psychoenergetic effect; beneficial effect on involutional and gerontological conditions as well as on the mnestic functions; keloid inclinations; spondylosis ankylo-poetics; diseases of the movement organs due to wear and tear; scle-rotic fundus; amyloidosis; morphea; fibrocytic mastopathy.
I veterinærmedicinen har de ifølge opfindelsen fremstil-15 lede forbindelser lignende anvendelsesområder som i humanmedicinen, dvs. fx hudskader (afskalning), sårheling og knoglebrud.In the veterinary medicine, the compounds prepared according to the invention have similar fields of application as in human medicine, ie. eg skin damage (peeling), wound healing and bone fractures.
Fremgangsmåden ifølge opfindelsen er ejendommelig ved det i krav 1's kendetegnende del angivne. - ·The process according to the invention is characterized by the characterizing part of claim 1. - ·
Ved fremgangsmåden ifølge opfindelsen fremstilles forbin-20 delserne med den almene formel I ved dannelse af en syreamidbinding. Herved sammenkobles et ved aminogruppen eller ved amino- og a-karboxyl-gruppen med en eller flere beskyttelsesgrupper eventuelt substitueret derivat af en α-aminodikarbonsyre over sin ω-karboxyl-gruppe med fx 2-aminoætansulfonsyre, 3-aminopropansulfonsyre eller 25 2-fosfonætanolamin. Ved dannelsen af syreamidbindingen kan der anvendes forskellige beskyttelsesgrupper. Koblingsmåden er aktivester-metoden (monografi vedrørende opbygning og selektiv fjernelse af beskyttelsesgrupper og koblingsmetoder: E. Schroder, K. Liibke: The peptides, bind 1: Methods of peptide 30 synthesis, Academic Press, 1965).In the process of the invention, the compounds of general formula I are prepared by forming an acid amide bond. Hereby, at the amino group or at the amino and α-carboxyl group, one or more protecting groups optionally substituted derivative of an α-aminodicarboxylic acid over its ω-carboxylic group is linked with, for example, 2-aminoethanesulfonic acid, 3-aminopropanesulfonic acid or 2-phosphonethanolamine. Various protecting groups can be used in the formation of the acid amide bond. The mode of coupling is the active ester method (monograph on structure and selective removal of protecting groups and coupling methods: E. Schroder, K. Liibke: The peptides, Volume 1: Methods of peptide synthesis, Academic Press, 1965).
Fremgangsmåden ifølge opfindelsen belyses nærmere i det følgende ved hjælp af nogle eksempler.The process according to the invention is illustrated in the following by means of some examples.
35 535 5
DK 155732BDK 155732B
Eksempel 1 5,42 g (li mmol) karbobenzyloxy-L-glutaminsyre-(a-ben-zyl)-y-p-nitrofenylester (Chem, Der. 96, 204» 1963) opløses i 50 5 ml pyridin. Opløsningen afkøles til 0°C og inden for en halv time tildryppes der under intensiv omrøring en opløsning af 1,25 g (10 mmol) taurin i 20 ml vand. Derpå sættes der 3»08 ml (22 mmol) tri-ætylamin til blandingen og afkøling og omrøring afbrydes. Blandingen henstår ved stuetemperatur i 72 timer og inddampes derpå 10 under vakuum. Remanensen opløses i 50 ml vand og der sættes IN saltsyre til den gule opløsning indtil den affarves. For at fjerne p-nitrofenolen rystes opløsningen ti gange med 50 ml æter hver gang. Den vandige fase inddampes under vakuum. Der vindes 6,9 g kar bobenzyloxy-γ- (α-benzyl )-L-glut amyltaurin-triætylammoniumsalt.Example 1 5.42 g (1 mmol) of carbobenzyloxy-L-glutamic acid (a-benzyl) -γ-p-nitrophenyl ester (Chem. Der. 96, 204 »1963) are dissolved in 50 ml of pyridine. The solution is cooled to 0 ° C and within half an hour a solution of 1.25 g (10 mmol) of taurine in 20 ml of water is added dropwise. Then 3 »08 ml (22 mmol) of triethylamine is added to the mixture and cooling and stirring are interrupted. The mixture is left at room temperature for 72 hours and then evaporated under vacuum. The residue is dissolved in 50 ml of water and IN hydrochloric acid is added to the yellow solution until it is decolorized. To remove the p-nitrophenol, shake the solution ten times with 50 ml ether each time. The aqueous phase is evaporated under vacuum. 6.9 g of carbene benzyloxy-γ- (α-benzyl) -L-glut amyltaurine-triethylammonium salt are obtained.
15 Relativ mobilitet i forhold til cysteinsyre ved papirelektroforese ved pH 6,5 er 0,5.Relative mobility to cysteic acid by paper electrophoresis at pH 6.5 is 0.5.
20 Eksempel 2 1,082 g (2,2 mmol) karbobenzyloxy-L-glutaminsyre-(a-ben-zyl)-y-p-nitrofenylester opløses i 6 ml af en blanding af pyridin og vand i forholdet 2:1. Til opløsningen sættes først 278 mg (2 . 25 mmol) homotaurin og derpå 0,59 ml (4,2 mmol) triætylamin. Den gule opløsning henstår ved stuetemperatur i 72 timer og inddampes derpå under vakuum. Den olieagtige remanens opløses i vand, neutraliseres med saltsyre og ekstraheres derpå til fjernelse af p-nitrofenol i en kontinuerlig ekstraktør med æter i otte timer. Den vandige fase 30 inddampes under vakuum. Der vindes 1,68 g karbobenzyloxy-y-(a-ben-zyl)-L-glutamylhomotaurin. Relativ mobilitet i forhold til cysteinsyre ved papirelektroforese ved pH 6,5 er 0,49.Example 2 1.082 g (2.2 mmol) of carbobenzyloxy-L-glutamic acid (α-benzyl) -γ-p-nitrophenyl ester are dissolved in 6 ml of a mixture of pyridine and water in a 2: 1 ratio. To the solution is first added 278 mg (2.25 mmol) of homotaurin and then 0.59 ml (4.2 mmol) of triethylamine. The yellow solution is left at room temperature for 72 hours and then evaporated under vacuum. The oily residue is dissolved in water, neutralized with hydrochloric acid and then extracted to remove p-nitrophenol in a continuous ether extractor for eight hours. The aqueous phase 30 is evaporated under vacuum. 1.68 g of carbobenzyloxy-γ- (α-benzyl) -L-glutamyl homotaurine are obtained. Relative mobility to cysteic acid by paper electrophoresis at pH 6.5 is 0.49.
35 635 6
DK 155732BDK 155732B
Eksempel 3 1.083 g (2,2 mmol) karbobenzyloxy-L-glutaminsyre-(a-ben-zyl)—y—p—nitrofenylester omsættes på den i eksempel 2 beskrevne 5 måde med 278 mg (2 mmol) N-metyltaurin. Der vindes 1,59 g karbo-benzyloxy-y-(α-benzyl)-L-glutamyl-N-metyltaurin. Dets relative mobilitet i forhold til cysteinsyre ved papirelektroforese ved pH 6,5 er 0,49.Example 3 1.083 g (2.2 mmol) of carbobenzyloxy-L-glutamic acid (α-benzyl) γ-p-nitrophenyl ester is reacted in the manner described in Example 2 with 278 mg (2 mmol) of N-methyltaurine. 1.59 g of carbo-benzyloxy-γ- (α-benzyl) -L-glutamyl-N-methyltaurine are obtained. Its relative mobility to cysteic acid by paper electrophoresis at pH 6.5 is 0.49.
1q Eksempel 4 2,87 g (6,6 mmol) karbobenzyloxy-L-glutaminsyre-(a-ben-zyl)-y-p-nitrofenylester opløses i 20 ml pyridin og der tilsættes en opløsning af 1,25 9 (6 mmol) L-cysteinsyremonohydrat i en blan-15 ding af 17 ml vand og 17 ml pyridin. Efter tilsætning af 2,6 ml' (18,6 mmol) triætylamin henstår reaktionsblandingen ved stuetemperatur i 72 timer. Derpå inddampes opløsningen under vakuum ved 30°C. Remanensen opløses i 20 ml vand, syrnes med koncentreret saltsyre og rystes derpå 15 gange med 10 ml æter hver gang. Den 20 vandige fase inddampes under vakuum ved 35°C. Der vindes karboben-zyloxy-y-(a-benzyl)-L-glutamyl-L-cysteinsyre. Forbindelsens relative mobilitet 1 forhold til cysteinsyre ved papirelektroforese ved pH 2,0 er 1,03.Example 4 2.87 g (6.6 mmol) of carbobenzyloxy-L-glutamic acid (α-benzyl) -yp-nitrophenyl ester are dissolved in 20 ml of pyridine and a solution of 1.25 g (6 mmol) of L is added. -cysteic acid monohydrate in a mixture of 17 ml of water and 17 ml of pyridine. After the addition of 2.6 ml of (18.6 mmol) of triethylamine, the reaction mixture is left at room temperature for 72 hours. The solution is then evaporated under vacuum at 30 ° C. The residue is dissolved in 20 ml of water, acidified with concentrated hydrochloric acid and then shaken 15 times with 10 ml of ether each time. The aqueous phase is evaporated under vacuum at 35 ° C. Carbobenzyloxy-γ- (α-benzyl) -L-glutamyl-L-cysteic acid is obtained. The relative mobility of the compound in relation to cysteic acid by paper electrophoresis at pH 2.0 is 1.03.
2b Eksempel 5 1.083 g (2,2 mmol) karbobenzyloxy-L-glutaminsyre-(a-ben-zyi)—y—p—nitrofenylester opløses i 6 ml af en tilberedt blanding af pyridin og vand i forholdet 2:1. Til opløsningen sættes først 30 282 mg (2 mmol) kolaminfosfat (US patentskrift nr. 2.730.542) og derpå 0,87 ml (6,2 mmol) triætylamin. Reaktionsblandingen henstår ved stuetemperatur i 72 timer og inddampes derpå under vakuum. Den videre oparbejdning foregår på den måde der er beskrevet i forbindelse med karbobenzyloxy-y-(a-benzyl)-L-glutamylhomotaurin (eksem-35 pel 2). Der vindes 1,25 g karbobenzyloxy-y-(a-benzyl)-L-glutamyl-kolaminfosfat. Produktets relative mobilitet i forhold til cysteinsyre ved papirelektroforese ved pH 2,0 er 0,9,2b Example 5 1.083 g (2.2 mmol) of carbobenzyloxy-L-glutamic acid (a-benzyl) -γ-p-nitrophenyl ester are dissolved in 6 ml of a prepared mixture of pyridine and water in a 2: 1 ratio. To the solution is first added 30 282 mg (2 mmol) of colamine phosphate (U.S. Patent No. 2,730,542) and then 0.87 ml (6.2 mmol) of triethylamine. The reaction mixture is left at room temperature for 72 hours and then evaporated under vacuum. Further work-up is carried out in the manner described in connection with carbobenzyloxy-γ- (α-benzyl) -L-glutamylhomotaurine (Example 2). 1.25 g of carbobenzyloxy-γ- (α-benzyl) -L-glutamyl-cholamine phosphate are obtained. The relative mobility of the product to cysteic acid by paper electrophoresis at pH 2.0 is 0.9,
DK 155732BDK 155732B
77
Eksempel 6 526 mg (1,1 mmol) karbobenzyloxy-L-asparaginsyre-(oc-benzyl)-|3-p-nitrofenylester (Chem.Ber. 97, 1789, 1964) opløses i 5 ml pyridin. Opløsningen afkøles til 0°C hvorpå der 5 i små portioner tilsættes en opløsning af 125 mg (1 mmol) taurin i 2 ml vand efterfulgt af 0,28 ml (2 mmol) triætyl-amin. Reaktionsblandingen henstår ved stuetemperatur i 48 timer og inddampes derpå under vakuum. Remanensen opløses i 5 ml vand og til den i begyndelsen gule opløsning sættes 1N 10 saltsyre indtil opløsningen er affarvet. Til fjernelse af p-nitrofenol udrystes opløsningen ti gange med 5 ml æter hver gang. Den vandige fase inddampes under vakuum. Der vindes 478 mg karbobenzyloxy-ø-(a-benzyl)-L-aspartyltaurin. Denne forbindelses relative mobilitet i forhold til cysteinsyre 15 ved papirelektroforese ved pH 6,5 er 0,51.Example 6 526 mg (1.1 mmol) of carbobenzyloxy-L-aspartic acid (oc-benzyl) - 3-p-nitrophenyl ester (Chem. Ber. 97, 1789, 1964) is dissolved in 5 ml of pyridine. The solution is cooled to 0 ° C, then a solution of 125 mg (1 mmol) of taurine in 2 ml of water is added in small portions followed by 0.28 ml (2 mmol) of triethylamine. The reaction mixture is left at room temperature for 48 hours and then evaporated under vacuum. The residue is dissolved in 5 ml of water and to the initially yellow solution is added 1N 10 hydrochloric acid until the solution is decolorized. To remove p-nitrophenol, the solution is shaken ten times with 5 ml of ether each time. The aqueous phase is evaporated under vacuum. 478 mg of carbobenzyloxy-α- (α-benzyl) -L-aspartyl taurine are obtained. The relative mobility of this compound relative to cysteic acid 15 by paper electrophoresis at pH 6.5 is 0.51.
Eksempel 7 526 mg (1,1 mmol) karbobenzyloxy-L-asparaginsyre-(a-2Q benzyl)-β-p-nitrofenylester og 139 mg (1 mmol) homotaurin omsættes på den i eksempel 6 beskrevne måde. Der vindes kar-bobenzyloxy-|3-(a-benzyl)-If-aspartylhomotaurin. Dets relative mobilitet i forhold til cysteinsyre ved papirelektroforese ved pH 6,5 er 0,5.Example 7 526 mg (1.1 mmol) of carbobenzyloxy-L-aspartic acid (α-2Q benzyl) -β-p-nitrophenyl ester and 139 mg (1 mmol) of homotaurine are reacted in the manner described in Example 6. Carbobenzyloxy-3- (a-benzyl) -If-aspartyl homotaurine is obtained. Its relative mobility to cysteic acid by paper electrophoresis at pH 6.5 is 0.5.
2525
Eksempel 8Example 8
Karbobenzyloxy-L-asparaginsyre-(α-benzyl)-β-p-nitro-fenylester og kolaminfosfat omsættes med hinanden på den i 2Q eksempel 5 beskrevne måde. Der vindes karbobenzyloxy-/3-(cx-benzyl)-L-aspartylkolaminfosfat. Dets relative mobilitet i forhold til cysteinsyre ved papirelektroforese ved pH 2,0 er 0,9.Carbobenzyloxy-L-aspartic acid (α-benzyl) -β-p-nitrophenyl ester and colamine phosphate are reacted with one another in the manner described in Example 5. Carbobenzyloxy- [3- (cx-benzyl) -L-aspartylcolamine phosphate is obtained. Its relative mobility to cysteic acid by paper electrophoresis at pH 2.0 is 0.9.
35 835 8
DK 155732BDK 155732B
De ved fremgangsmåden ifølge opfindelsen fremstillede forbindelsers biologiske virkning skal i det følgende belyses i to biologiske forsøgsrapporter, A og B. I disse forsøgsrapporter vises den biologiske virkning for fire forskellige typer af 5 forbindelser med den almene formel I. De undersøgte forbindelser har alle ubeskyttede N-terminale og C-terminale grupper, 1 1 dvs. R er hydrogen og A er hydroxy. Forbindelser med den al- mene formel I, hvor R er forskellig fra hydrogen og/eller hvor 1 A er forskellig fra hydroxy har den samme biologiske virkning 10 som de tilsvarende ubeskyttede aminosyrederivater, idet man må forvente at beskyttelsesgrupperne fraspaltes i organismen.The biological effect of the compounds of the invention according to the invention will be elucidated in two biological test reports, A and B. In these test reports, the biological effect of four different types of 5 compounds of general formula I. The compounds tested have all unprotected N -terminal and C-terminal groups, 1 1 ie. R is hydrogen and A is hydroxy. Compounds of general formula I wherein R is different from hydrogen and / or where 1A is different from hydroxy have the same biological effect 10 as the corresponding unprotected amino acid derivatives, one having to expect the protecting groups to be cleaved in the organism.
Biologisk forsøgsrapport A.Biological Test Report A.
1515
Undersøgelse af γ-L-glutamyltaurin som i nærværende .rapport betegnes litoralon.Examination of γ-L-glutamyltaurine as in this report is called litoralon.
I de efterfølgende tabeller 1-6 er forsøgsresultaterne vist som middelværdier + standardafvigelse med antallet af bestem-2Q melser i parentes. Bestemmelse af om der er signifikant forskel mellem kontrolforsøg og forsøg med behandlede dyr blev foretaget med Students t-test.In the following Tables 1-6, the experimental results are shown as mean values + standard deviation with the number of determinations in parentheses. Determination of whether there is a significant difference between control trials and trials in treated animals was done with Student's t-test.
Tabel 1 25 Litoraions virkning på vitamin A-koncentrationen i serum.Table 1 25 Effect of Litoraion on vitamin A concentration in serum.
Gruppe litoralon vitamin A-koncentration i serum _ug/dag_mg %_ I. Kontrol - 28,3+0,7 (20) 30 II. 0,1 41,9 + 1,0X (20) III. 0,3 32,9 + 1,1XX (20) IV. 1,0 27,4 + 0,6 (20) x P < 0,001 25 xx P < 0,01Group of litoralone vitamin A concentration in serum _ug / day_mg% _ I. Control - 28.3 + 0.7 (20) 30 II. 0.1 41.9 + 1.0X (20) III. 0.3 32.9 + 1.1XX (20) IV. 1.0 27.4 + 0.6 (20) x P <0.001 25 xx P <0.01
DK 155732BDK 155732B
9 20 Sprague Dawley rotter (10 hanner og 10 hunner) vejende 180-200 g behandledes oralt med de i tabel 1 angivne daglige doser litoralon i form af en vandig opløsning i en periode på 8 dage. På den 9. forsøgsdag aflivedes dyrene ved dekapitering og 5 blodet opsamledes. Vitamin A-koncentrationen i serumet bestemtes ved Neeld og Pearsons metode.9 20 Sprague Dawley rats (10 males and 10 females) weighing 180-200 g were orally treated with the daily doses of litoralone in Table 1 in the form of an aqueous solution for a period of 8 days. On the 9th test day, the animals were sacrificed by decapitation and the blood was collected. The vitamin A concentration in the serum was determined by Neeld and Pearson's method.
Tabel 2Table 2
Virkning af litoralon og vitamin A på granulomdannelse frem- 10 kaldt af implanterede vatkuqler_Effect of Litoralon and Vitamin A on Granule Formation Caused by Implanted Cotton Balls
Gruppe Dosis Tør vægt af . x .,, Ί granulomGroup Dose Dry weight off. x. ,, Ί granuloma
Vitamin A litoralon lokal lokal oral y 15 mg ug yg/dag_ I. Kontrol - - - 52 + 1,0 (24) II. Kontrol +Vitamin A litoralon local local oral y 15 mg ug yg / day_ I. Control - - - 52 + 1.0 (24) II. Control +
Opløsningsmiddel - - - 54+3,1(8) III. 2 - - 64 + 2,5 (8) 20 “ IV. 2 0,1 - 65 + 2,7 (8) V. - - 0,1 73 + 2,9 (8) VI. 2 - 0,1 90 + 4,1 (8) x Hoffmann La Roche 25Solvent - - - 54 + 3.1 (8) III. 2 - - 64 + 2.5 (8) 20 “IV. 2 0.1 - 65 + 2.7 (8) V. - - 0.1 73 + 2.9 (8) VI. 2 - 0.1 90 + 4.1 (8) x Hoffmann La Roche 25
Forskellen er signifikant: mellem gruppe II og III ved P < 0,05, mellem II og V ved P < 0,001, og mellem V og VI ved P < 0,01. Granulomdannelsen bestemtes ifølge Lee et al med ^ Sprague-Dawley hanrotter vejende 110-120 g. Tamponerne fjernedes fra de dorsolaterale subkutane implantationer efter 10 dage og vejedes efter tørring til konstant vægt ved 65°C.The difference is significant: between groups II and III at P <0.05, between II and V at P <0.001, and between V and VI at P <0.01. The granule formation was determined according to Lee et al with male Sprague-Dawley rats weighing 110-120 g. The tampons were removed from the dorsolateral subcutaneous implants after 10 days and weighed after drying to constant weight at 65 ° C.
3535
DK 155732BDK 155732B
1010
cm cm cm ω i Icm cm cm ω in I
Η Η Η Ό Ό (U OJO Η Η Ό Ό (U OJ
— — — Hi h 4J < Λ- - - Hi h 4J <Λ
g O C Wg O C W
cm r-~ oo Λ >i U ftcm r- ~ oo Λ> i U ft
con •tf'd' <r ^ w fi W ^ & Ucon • tf'd '<r ^ w fi W ^ & U
ft o o oo o to 0) Cl) 0 O - - » - - » +i Λ fcr> -P Cn H o oo oo Η 3.Π3-ΡΟ + 1 +1 +1 «. °d m <u 1 1 iw ft ro h d rfj T3 s 3 dl 01ft o o oo o to 0) Cl) 0 O - - »- -» + i Λ fcr> -P Cn H o oo oo Η 3.Π3-ΡΟ + 1 +1 +1 «. ° d m <u 1 1 iw ft ro h d rfj T3 s 3 dl 01
3 Μ o ω Λ U3 Μ o ω Λ U
0) d © oo © W + H d0) d © oo © W + H d
oo co r·» o r~ o CO 4J d Hoo co r · »o r ~ o CO 4J d H
λ; Η O «S' CM HH φ ·© 2 ·Η Ή dλ; Η O «S 'CM HH φ · © 2 · Η Ή d
to »». - » κ» tr> ft Othaw "". - »κ» tr> ft O
o CM Ο HO CM O ·& (D <c S-l CO 4-1 fccj +| +1 +1 tfl H CQ Ό 0) C (0 c ωo CM Ο HO CM O · & (D <c S-l CO 4-1 fccj + | +1 +1 tfl H CQ Ό 0) C (0 c ω
03 0 M &> 0 -η H03 0 M &> 0 -η H
ft O g X > Xft O g X> X
O co tnO co tn
CD H CT *4-10 - T3 CCD H CT * 4-10 - T3 C
Pi ^ CM CM ΙΟ Η·Μ* H O' H ft Η Ή 00 Ο CD Ο 00 Ο Ο Η 0 Ο1 (¾¾ - - «. - »% «. Η tT » 43 d o o o o o o o ti O d 3 ® + 1 +1 +1 <5 o © v Ό » Xi ©Pi ^ CM CM ΙΟ Η · Μ * HO 'H ft Η Ή 00 Ο CD Ο 00 Ο Ο Η 0 Ο1 (¾¾ - - «. -»% «. Η tT» 43 dooooooo ti O d 3 ® + 1 +1 +1 <5 o © v Ό »Xi ©
^ IH CT^ IH CT
ft tn < (0 <h Hft tn <(0 <h H
0 W d Φ0 W d Φ
. r^cMco'04-iD<DlP. r ^ cMco'04-iD <DLP
CD CM H CD OH <DO C 4-1 HCD CM H CD OH <DO C 4-1 H
e (0 cn o cn o m o > o · H tn 03 U.....- ε O CD ft •Η HOHOHO φ O Ό > >i 3 P - C <D ηe (0 cn o cn o m o> o · H tn 03 U .....- ε O CD ft • Η HOHOHO φ O Ό>> i 3 P - C <D η
S__Id (D ε w Ό -HS__Id (D ε w Ό -H
4J A4 U © S <>d Λ crf Ή ί>ι »C ^ Η M4 Q U · !4 CO CM H CD d ft4J A4 U © S <> d Λ crf Ή ί> ι »C ^ Η M4 Q U ·! 4 CO CM H CD d ft
Η Γ— CM CD CM in CM d · Λ tj! CDCM Γ— CM CD CM in CM d · Λ tj! CD
nrfl ft coo cm o ho tT tn £ d 'dnrfl ft coo cm o ho tT tn £ d 'd
+) cj * * ~ «· - «· Η σι Ό . K+) cj * * ~ «· -« · Η σι Ό. K
r-IG OOOOOO BOH *Hr-IG OOOOOO BOH * H
CD 03 +1 +1 +1 in 03 ο d CDCD 03 +1 +1 +1 in 03 ο d CD
n g Η H co CTn g Η H co CT
B H CD I - 4-1 HB H CD I - 4-1 H
ft H O 4J h d -Q. ·ft H O 4J h d -Q. ·
m H'H'dCDCHHm H'H'dCDCHH
Q. Η H J4 dP Ο ·Η d * 1^* H d 00 0 © rij CM H CO OH 4-1 ε CT H d 4-1Q. Η H J4 dP Ο · Η d * 1 ^ * H d 00 0 © row CM H CO OH 4-1 ε CT H d 4-1
03 <ro r- o cto tT ίτ 3 ft <D <D03 <ro r- o cto tT ίτ 3 ft <D <D
<h HO **· » ». vv OroCH»d tS<h HO ** · »». vv OroCH »d tS
(0 OOOOOO > I ft ε 0 c d) +1 +1 +1 H to H 0 4-1 d C η ε ·Η Ό « CD d(0 OOOOOO> I ft ε 0 c d) +1 +1 +1 H to H 0 4-1 d C η ε · Η Ό «CD d
So cd m cd ε ε o, CD tT 4-1 Λ 4-1 +j c o ft © -H d 0) TJ +»So cd m cd ε ε o, CD tT 4-1 Λ 4-1 + j c o ft © -H d 0) TJ + »
-H H CM *=r ft H d CD > (D-H H CM * = r ft H d CD> (D
h 2 cm in co in h 3 0 k -Η > Ωh 2 cm in co in h 3 0 k -Η> Ω
Kc* p,j ^ ^ ^ v η M *d 'H Cn -H 2 co o tn o co o tn φ ft d d co ·Kc * p, j ^^^ v η M * d 'H Cn -H 2 co o tn o co o tn φ ft d d co ·
> +1 +1 +1 ^ ε 0 © d <u\ O> +1 +1 +1 ^ ε 0 © d <u \ O
•a ε n -p 3 © μ ft ^ μ ε n Η © o © © © d ocfl H 4-1 d ε +* ft "3· CO CD CM O (D 4-1 Ή — 03 4-*• a ε n -p 3 © µ ft ^ µ ε n Η © o © © © d ocfl H 4-1 d ε + * ft "3 · CO CD CM O (D 4-1 Ή - 03 4- *
»•cm »-cm «-Η ε ο ε - ft © <D»• cm» -cm «-Η ε ο ε - ft © <D
tr> d •M' - cm »< ^ » H d E-> U Λ ^ e U HO HO HO © d I H ·— © H +1 +1 +1 β 5 «a ^ ^ y c___ © 43 ·»— d u « y -f- Η ·Η 01 H tntn H >1 2 d © · © •η ε ε © © ft o 4-) λ! λ > Otn 44 Η <3 Η Ο 0) ο Η 44 03 & Ρ3 d Η 3 £tr> d • M '- cm »<^» H d E-> U Λ ^ e U HO HO HO © d IH · - © H +1 +1 +1 β 5 «a ^^ y c___ © 43 ·» - du «y -f- Η · Η 01 H tntn H> 1 2 d © · © • η ε ε © © ft o 4-) λ! λ> Otn 44 Η <3 Η Ο 0) ο Η 44 03 & Ρ3 d Η 3 £
01 HH MdM ftMO01 HH MdM ftMO
c O ScnOQCTOOXl© O M 2 ft - h I 6 +* *4 .c O ScnOQCTOOXl © O M 2 ft - h I 6 + * * 4.
H 44 ft <| O ©·ΗΤ3 44Μ d © d < rø dOHdO© c. q. Offl · tT H O Ή 44 O ft« -54 ©ΛίΑίΟε 4J 3 · HH H CO 03 Ή © •Η Η · Η H id ft H »H tT H 44 j O Η Η H+ 03ί>44θΧθ3 1 1H 44 ft <| O © · ΗΤ3 44Μ d © d <rø dOHdO © c. Q. Offl · tT H O Ή 44 O ft «-54 © ΛίΑίΟε 4J 3 · HH H CO 03 Ή © • Η Η · Η H id ft H» H tT H 44 j O Η Η H + 03ί> 44θΧθ3 1 1
DK 155732BDK 155732B
tn 0) Λ ^ r*. (O Φtn 0) Λ ^ r *. (O Φ
VD l£> Ο Ό PVD l £> Ο Ό P
^ · §^ · §
O PUP
tn XX m tn id X X <l> Ό σι H rH ri in «tf β Ρ Λ «tf H m H m Η Φ tutn XX m tn id X X <l> Ό σι H rH ri in «tf β Ρ Λ« tf H m H m Η Φ tu
• Honono O-HIS• Honono O-HIS
o ·. - - - - - > po ·. - - - - -> p
O O o O O O (Otfl-HO O o O O O (Otfl-H
+i +1 +1 ϋ s+ i +1 +1 ϋ s
tn rHtn rH
G) Q) -rHG) Q) -rH
C rH ω tn XX p id XX Φ Ό · O) O ΰφ πν mn Ρ Φ Ρ β C\| O O rH O rH id g φ Φ • rH O Cl O ri O P 01> O »»»·«·*»"* Η p 0 ΦC rH ω tn XX p id XX Φ Ό · O) O ΰφ πν mn Ρ Φ Ρ β C \ | O O rH O rH id g φ Φ • rH O Cl O ri O P 01> O »» »·« · * »" * Η p 0 Φ
CMOOOOOO Ρ Φ U PCMOOOOOO Ρ Φ U P
+ | +1 +| W a -Θ.+ | +1 + | W a -Θ.
φ ·Ρ φφ · Ρ φ
Ρ β tn w id Η Φ tn χ Η CΡ β tn w id Η Φ tn χ Η C
tn 0 β tn Φ ιΰ XX to φ in Όη'ΗΓΜνοΗΐη Η ,β U >ι rHHCOOOrH ο Ό • rH Ο Η Ο ΓΗ Ο - Φ Φ r—. η ****** ο χ3 β id UHOOOOOO Φ > Ρ Ο +1 +1 +1 V η ·Ρ Ρ rH > tn Λ ft id β -Ρ 13 Φ Φ tn Ό β tn \ φ ·Ρ «tf Φ tn > -Ρtn 0 β tn Φ ιΰ XX to φ in Όη'ΗΓΜνοΗΐη Η, β U> ι rHHCOOOrH ο Ό • rH Ο Η Ο ΓΗ Ο - Φ Φ r—. η ****** ο χ3 β id UOOOOOO Φ> Ρ Ο +1 +1 +1 V η · Ρ Ρ rH> tn Λ ft id β -Ρ 13 Φ Φ tn Ό β tn \ φ · Ρ «tf Φ tn> -Ρ
g tn «ud Η Ug tn «ud Η U
w ιΰ fltn h^1 H«i Φ a Φ Ρ T3 HH LD o r* O Ρ Λw ιΰ fltn h ^ 1 H «i Φ a Φ Ρ T3 HH LD o r * O Ρ Λ
g rH O rH O rH O fi M id Pg rH O rH O rH O fi M id P
^ j3 ****** * id φ -Ρ φ •HP' OO oo oo Ai P > rH U +1 +1 +1 -ri P p·^ j3 ****** * id φ -Ρ φ • HP 'OO oo oo Ai P> rH U +1 +1 +1 -ri P p ·
φ ρ ·Η Ρ Ό. Pφ ρ · Η Ρ Ό. P
X) (d <-H -Ρ Ρ Φ aX) (d <-H -Ρ Ρ Φ a
<d φ -Ρ β Ό D 'O<d φ -Ρ β Ό D 'O
EH > w 5 0EH> w 5 0
•Η ·Η Ή rH• Η · Η Ή rH
a W Φ Λ g tn X G -ρ ρ υ Ό(Λ IN οω ΡΦγΗγΗa W Φ Λ g tn X G -ρ ρ υ Ό (Λ IN οω ΡΦγΗγΗ
•Η >d <!Ό ΙΛΗ hO φ tn Id S• Η> d <! Ό ΙΛΗ hO φ tn Id S
Ο Ο Ο rH Ο Η Ο Ό.Ρ •η . ^ ^ ~ t n οι ο t nH Ο Ο rH Ο Η Ο Ό.Ρ • η. ^ ^ ~ t n οι ο t n
i-η tn o o o o o o id Pi-η tn o o o o o o id P
ri +1 +1+1 Ό Ρ P |dri +1 + 1 + 1 Ό Ρ P | d
01 (p φ P01 (p φ P
• > P•> P
οι η · ·Η 4J rH rH tn 13οι η · · Η 4J rH rH tn 13
qj o 13 Pqj o 13 P
irj β O βirj β O β
o φ Φ - ·Η No φ Φ - · Η N
h s H 'V ° ^ t! η -π ro m in vd nr- H o > (d P oo mo oo oo id v Φ Λh s H 'V ° ^ t! η -π ro m in vd nr- H o> (d P oo mo oo oo id v Φ Λ
0(3 rH O O O rH O * * Ρ Η P0 (3 rH O O O rH O * * Ρ Η P
(¾ . * * * * V«. O O P (I, ρ β(¾. * * * * V «. O O P {I, ρ β
O O O O O O O OO O O O O O O O
tn +| +| +1 v v Φ τι β d β Φ O Φ •p Hl Al p > H tn d Φ id h v* ·· ·· Ρ Φ ρ ©.tn + | + | +1 v v Φ τι β d β Φ O Φ • p Hl Al p> H tn d Φ id h v * ·· ·· Ρ Φ ρ ©.
u dtnoioiidPOPu dtnoioiidPOP
•ri β Old ββΡβΡ-Η• ri β Old ββΡβΡ-Η
*> OtnHO (didPid-P*> OtnHO (didPid-P
h id idX. At X P a: PI β οι h idO P tn -ρ -ρ οι -ρ φ β o P\ O Ρ- Ρ Ρ Φ P · uh id idX. At X P a: PI β οι h idO P tn -ρ -ρ οι -ρ φ β o P \ O Ρ- Ρ Ρ Φ P · u
O P 0 tn Ρ ·ρ ·ρ (¾ ·ρ tn OO P 0 tn Ρ · ρ · ρ (¾ · ρ tn O
Η ΡΡ^-ΡΟβββΑίΡ id Φ β ·Ρ PlrH tn tn tn Φ P Qj O PI tn ·ρ ·Ρ ·ρ ci g o a « · ω to in i _ ρ d . η mu •ρρ · Η η X Ρ-Φ Η Η Η XX Φ Ν > 12 DK 1557328Η ΡΡ ^ -ΡΟβββΑίΡ id Φ β · Ρ PlrH tn tn tn Φ P Qj O PI tn · ρ · Ρ · ρ ci g o a «· ω to in i _ ρ d. η mu • ρρ · Η η X Ρ-Φ Η Η Η XX Φ Ν> 12 DK 1557328
Tabel 5Table 5
Litoralons virkning på Rana dalmatina's metamorfoseThe effect of Litoralon on the metamorphosis of Rana dalmatina
Gruppe Kropslængde Halelængde 5 _mm_mm_Group Body length Tail length 5 _mm_mm_
Kontrol 45,9 +0/2 31,4+0,2 (60)Control 45.9 +0/2 31.4 + 0.2 (60)
Behandlede dyr 40,2 + 0,2X 26,7 + 0,2X (60) x Signifikans: P < 0,001 i ηTreated animals 40.2 + 0.2X 26.7 + 0.2X (60) x Significance: P <0.001 in η
Forsøget udførtes med larver af Rana dalmatina med en alder på 30 dage, en kropslængde på 20-25 mm, og med allerede synlige fremspirende bagben. I løbet af en periode på 30 dage blev forsøgsdyrene anbragt i postevand indeholdende 0,5 yg/ml litoralon i to timer hver dag. Kontrolgruppen blev anbragt i 15 postevand uden tilsætning af litoralon. Haletudserne måltes på den 30. dag.The experiment was conducted with larvae of Rana dalmatina with a age of 30 days, a body length of 20-25 mm, and with already visible projecting hind legs. Over a period of 30 days, the test animals were placed in tap water containing 0.5 µg / ml litoralon for two hours each day. The control group was placed in 15 tap water without the addition of litoralone. The tails were measured on the 30th day.
Tabel 6 2Q Litoralons virkning på blodsukkerniveauetTable 6 2Q Litoralone's effect on blood sugar levels
Gruppe I. Undersøgelse II. Undersøgelse _mg %_mg %_Group I. Study II. Survey _mg% _mg% _
Kontrol 94 + 3,6 (10) 94 + 4,09 (10)Control 94 + 3.6 (10) 94 + 4.09 (10)
Behandlede dyr 82,4 + 3,8 (10) 81+1,32 (10) 25Treated animals 82.4 + 3.8 (10) 81 + 1.32 (10) 25
Signifikans ved I. undersøgelse: P < 0,05 Signifikans ved II. undersøgelse: P < 0,01Significance at I. study: P <0.05 Significance at II. study: P <0.01
Hvide CGY-hanrotter med legemsvægt 160-180 g anvendtes til forsøget. Dyrene holdtes på en standard diæt. Der blev taget 2Q blodprøver på den 5. forsøgsdag efter 18 timers faste. Blodsukkerbestemmelserne udførtes efter metoden ifølge E. Hultman.Male CGY white body rats 160-180 g were used for the experiment. The animals were kept on a standard diet. 2Q blood samples were taken on the 5th day of trial after 18 hours of fasting. The blood glucose assays were performed according to the method of E. Hultman.
Litoralon blev indgivet oralt i daglige doser på 1 yg/kg.Litoralon was given orally at daily doses of 1 µg / kg.
35 1335 13
DK 155732BDK 155732B
Biologisk forsøgsrapport B.Biological Test Report B.
Undersøgelse af diverse forbindelser med formel I.Investigation of various compounds of formula I.
1. β-aspartyl-N-metyltaurin 5 a) Virkning på blodsukkerniveauet Kontrol 107 mg %1. β-Aspartyl-N-methyltaurine 5 a) Effect on blood sugar level Control 107 mg%
Behandlede dyr 93 mg %Treated animals 93 mg%
Signifikans: P < 0,05Significance: P <0.05
Til prøverne anvendtes 20-20 rotter. Målingerne gennem-10 førtes efter 18 timers faste. Den anvendte dosis var 1 yg/kg legemsvægt i 4 dage i form af en opløsning ved oral indgift.20-20 rats were used for the samples. Measurements were carried out -10 after 18 hours of fasting. The dose used was 1 µg / kg body weight for 4 days in the form of a solution by oral administration.
b) Forøgende virkning på vitamin A-niveauet i serumb) Increasing effect on serum vitamin A level
Oral dosis Kone., vitamin A, mg% 15 yg/200 g legemsvægt 0 (kontrol) 8,5 5 11,0 1 11,5 0,3 12,5 20 0,1 16,1 0,05 14,8 0,01 12,5 0,005 10,5 2,. Signifikans: P < 0,01Oral dose Conical vitamin A, mg% 15 µg / 200 g body weight 0 (control) 8.5 5 11.0 1 11.5 0.3 12.5 20 0.1 16.1 0.05 14.8 0.01 12.5 0.005 10.5 2 ,. Significance: P <0.01
Til forsøgene anvendtes 20-20 Wistar hanrotter med legemsvægt 200-220 g.For the experiments, 20-20 Wistar male rats weighing 200-220 g were used.
Forsøgsperiode: 6 dage.Trial period: 6 days.
c) Virkning på blodets siliciumniveau:c) Effect on blood silicon level:
Silicium (mg/g blod) 0 timer 20 dage_40 dage_Silicon (mg / g blood) 0 hours 20 days_40 days_
Kontrolgruppe 0,110+0,004 0,120+0,010 0,154+0,015Control group 0.110 + 0.004 0.120 + 0.010 0.154 + 0.015
Behandlingsgruppe 15 yg/dag 0,100+0,005 0,315+0,014 0,345+0,015Treatment group 15 µg / day 0.100 + 0.005 0.315 + 0.014 0.345 + 0.015
Behandlingsgruppe II 10 yg/dag 0,107+0,009 0,370+0,119 0,360+0,017 xx Signifikans: P < 0,001 14Treatment Group II 10 µg / day 0.107 + 0.009 0.370 + 0.119 0.360 + 0.017 xx Significance: P <0.001 14
DK 155732BDK 155732B
Resultaterne er signifikante fra 20. dag ved niveau P < 0,001. Forsøgene udførtes på indavlede hankaniner med legemsvægt 2,5-3 kg. Den aktive bestanddel blev indgivet oralt i de i tabellen viste daglige doser. Bestemmelsen af silicium udførtes i-5 følge Gaubatz's metode (Gaubatz E., Klin. Wschrft. 14, 1753, 1935) i 5 ml blodprøver, som blev taget fra dyrenes ørevene.Results are significant from day 20 at level P <0.001. The experiments were performed on inbred male rabbits of body weight 2.5-3 kg. The active ingredient was administered orally in the daily doses shown in the table. The determination of silicon was carried out i-5 according to Gaubatz's method (Gaubatz E., Clin. Wschrft. 14, 1753, 1935) in 5 ml blood samples taken from the animals' ears.
Hver gruppe bestod af fem dyr.Each group consisted of five animals.
d) Virkning af j3-aspartyl-N-metyl-taurin og vitamin A på den 10 granulomfremkaldende virkning forårsaget af implantation af vat:_d) Effect of β-aspartyl-N-methyl-taurine and vitamin A on the 10 granulogenic effect caused by the implantation of cotton wool:
Gruppe Dosis Vægt af tør-Group Dose Weight of dry
Vitamin Ax 3-aspartyl-N- ret 9ranulomVitamin Ax 3-aspartyl-N- ret 9ranuloma
t . IRCTt. IRCT
metyltaurm lokal lokal oral 15 _mg_yg yg/dag____methyl taurus local local oral 15 mg / day / day ____
Kontrol I. - - - 54+1,7Control I. - - - 54 + 1.7
Kontrol II. + opløsningsmiddel - - - 55+3,4Control II. + solvent - - - 55 + 3.4
Behandlingsgruppe III. 2 - - 66+12,5 2g Behandlingsgruppe IV. 2 0,1 - 67 + 2,6Treatment Group III. 2 - - 66 + 12.5 2g Treatment Group IV. 2 0.1 - 67 + 2.6
Behandlingsgruppe V. - - 0,1 79+2,8Treatment group V. - - 0.1 79 + 2.8
Behandlingsgruppe VI. 2 - 0,1 96+4,4 x Hoffmann la Roche 25 Forskellene er signifikante som følger:Treatment Group VI. 2 - 0.1 96 + 4.4 x Hoffmann la Roche 25 The differences are significant as follows:
Mellem gruppe II og III P < 0,05, mellem gruppe II og V P < 0,001 og mellem gruppe V og VI P < 0,01.Between groups II and III P <0.05, between groups II and V P <0.001 and between groups V and VI P <0.01.
Bestemmelsen af granulom udførtes på grupper på hver fem Sprague-Dawley hanrotter med legemsvægt 110-120 g ved me-30 toden ifølge Lee et al (Lee K.H., Fu Ch.Ch., Spencer M.R.The determination of granuloma was performed on groups of five male Sprague-Dawley body weights 110-120 g by the method of Lee et al (Lee K.H., Fu Ch.Ch., Spencer M.R.
Tong T.G. og Poon R.J., Pharm. Sci., 62, 895, 1973). De dor-solateralt subkutant implanterede tamponer fjernedes efter 10 dage og måltes efter tørring ved 65°C til konstant vægt.Tong T.G. and Poon R.J., Pharm. Sci., 62, 895, 1973). The dor- solaterally subcutaneously implanted tampons were removed after 10 days and measured after drying at 65 ° C to constant weight.
35 1535 15
DK 155732BDK 155732B
2. β-Aspartyl-homotaurin, a) Virkning på blodsukkerniveauet2. β-Aspartyl homotaurine, a) Effect on blood sugar level
Kontrolgruppe 105 mg%Control group 105 mg%
Behandlet gruppe 94 mg% 5 Signifikans, antal forsøgsdyr og forsøgsmetode var som angivet under pkt. 1 a) ovenfor.Treated group 94 mg% 5 Significance, number of test animals and test method were as given in section. 1 a) above.
b) Forøgende virkning på vitamin A-niveauet i serumb) Increasing effect on serum vitamin A level
Oral dosis Koncentration vitamin AOral dose Vitamin A concentration
10 pg/200 g legemsvægt mg% 0 (kontrol) 8,6 5 12,0 1 13,5 0,3 14,0 15 0,1 15,8 0,05 15,0 0,01 12,0 0,005_10,0_10 pg / 200 g body weight mg% 0 (control) 8.6 5 12.0 1 13.5 0.3 14.0 15 0.1 15.8 0.05 15.0 0.01 12.0 0.005_10 , 0_
Signifikans, antal forsøgsdyr og forsøgsmetode var som angivet ovenfor under pkt. Ib).Significance, number of test animals and test method were as indicated above under section. Ib).
c) Virkning på blodets siliciumniveau:c) Effect on blood silicon level:
Silicium (mg/g blod) 25 _0 timer _20 dage_40 dage__Silicon (mg / g blood) 25 _0 hours _20 days_40 days__
Kontrolgruppe 0,104+0,009 0,134+0,015 0,157+0,020Control group 0.104 + 0.009 0.134 + 0.015 0.157 + 0.020
Behandlingsgruppe I. 5yg/dag 0,094+0,007 0,309+0,014 0,340+0,014Treatment group I. 5yg / day 0.094 + 0.007 0.309 + 0.014 0.340 + 0.014
Behandlingsgruppe II. 10 pg/dag 0,109+0,010 0,372+0,120 0,363+0,018ΛΛ 30 Signifikans, antal forsøgsdyr, arrangement og bestemmel sesmetode som angivet ovenfor under pkt. 1 c).Treatment Group II. 10 pg / day 0.109 + 0.010 0.372 + 0.120 0.363 + 0.018ΛΛ 30 Significance, number of test animals, arrangement and method of determination as indicated above under section. 1 c).
35 1635 16
DK 155732BDK 155732B
d) Virkning af β-aspartyl-homotaurin og vitamin A på den granu-lomfremkaldende virkning af implantation af vat;_(d) Effect of β-aspartyl homotaurin and vitamin A on the granulomatous effect of cotton implantation;
Dosis Vægt af tørretDose Weight of dried
Vitamin Ax β-aspartyl- granulom 5 lokal homotaurin g mg lokal oral _μg yg/dag_Vitamin Ax β-aspartyl granuloma 5 local homotaurin g mg local oral _µg yg / day_
Kontrolgruppe I - - - 52+1,5Control group I - - - 52 + 1.5
Kontrolgruppe II - - - 53+3,2 + opløsningsmiddel 10 Behandlingsgruppe III. 2 - - 64+12,3Control group II - - - 53 + 3.2 + solvent 10 Treatment group III. 2 - - 64 + 12.3
Behandlingsgruppe IV. 2 0,1 - 65+2,4Treatment Group IV. 2 0.1 - 65 + 2.4
Behandlingsgruppe V. - - 0,1 77+2,6Treatment group V. - - 0.1 77 + 2.6
Behandlingsgruppe VI._2_ 0,1_94 + 4,2__ x Hoffmann la Roche 15Treatment group VI._2_ 0.1_94 + 4.2__ x Hoffmann la Roche 15
Signifikans, antal forsøgsdyr, arrangement og bestemmelsesmetode var som angivet ovenfor under punkt ld).Significance, number of test animals, arrangement and method of determination were as indicated above under point (ld).
3. γ-Glutamyl-kolaminfosfat.3. γ-Glutamyl-Colamine Phosphate.
a) Virkning på blodsukkerniveauet 20(a) Effect on blood sugar levels 20
Kontrolgruppe 104 mg%Control group 104 mg%
Behandlingsgruppe 93 mg%Treatment group 93 mg%
Signifikans, antal forsøgsdyr, arrangement og dosering var som angivet ovenfor under punkt la).Significance, number of test animals, arrangement and dosage were as indicated above under point 1a).
25 b) Forøgende virkning på vitamin A-niveauet i serum25 b) Increasing effect on serum vitamin A level
Oral dosis Vitamin A-koncentration yg/200 g legemsvægt_mg%_________ 0 (kontrol) 8,8 30 5 12'3 1 13,4 0,3 14,3 0,1 16,0 0,05 15,5 0,01 11,2 35 0,005_9j2_ 17Oral dose of Vitamin A concentration yg / 200 g body weight_mg% _________ 0 (control) 8.8 30 5 12'3 1 13.4 0.3 14.3 0.1 16.0 0.05 15.5 0.01 11.2 35 0.005_9j2_ 17
DK 155732BDK 155732B
Signifikans, antal forsøgsdyr, arrangement og bestemmelsesmetode var som angivet ovenfor under punkt 1 b).Significance, number of test animals, arrangement and method of determination were as indicated above under point 1 (b).
c) Virkning på blodets siliciumniveau: 5 Silicium (mg/g blod) _0 timer_20 dage_40 dage_c) Effect on blood silicon level: 5 Silicon (mg / g blood) _0 hours_20 days_40 days_
Kontrolgruppe 0,106+0,011 0,136+0,017 0,159+0,022Control group 0.106 + 0.011 0.136 + 0.017 0.159 + 0.022
Behandlingsgruppe xx I 5 yg/dag 0,096+0,009 0,311+0,016 0,340+0,017 .. Behandlingsgruppe vv xx 10 II 10 yg/dag 0,111+0,011 0,374+0,121xx 0,365+0,019Treatment group xx I 5 µg / day 0.096 + 0.009 0.311 + 0.016 0.340 + 0.017 .. Treatment group vv xx 10 II 10 µg / day 0.111 + 0.011 0.374 + 0.121xx 0.365 + 0.019
Signifikans, antal forsøgsdyr, arrangement og bestemmelsesmetode var som angivet ovenfor under punkt 1 c).Significance, number of test animals, arrangement and method of determination were as indicated above under point 1 (c).
d) Virkning af γ-glutamyl-kolaminfosfat og vitamin A på den 1 s granulomfremkaldende virkning af vatimplantation;_(d) Effect of γ-glutamyl-cholamine phosphate and vitamin A on the 1 s granuloma-inducing effect of water implantation;
Dosis Vægt af tør ret granulomDose Weight of dry straight granuloma
Vitamin Ax γ-glutamyl- mg lokal kolaminfosfat mg lokal oral 2Q _yg yg/dag_Vitamin Ax γ-glutamyl mg local colamine phosphate mg local oral 2Qg / day / day
Kontrolgruppe I. - - - 49+1,2Control group I. - - - 49 + 1.2
Kontrolgruppe II. + opløsningsmiddel - - - 50+2,9Control group II. + solvent - - - 50 + 2.9
Behandlingsgruppe III. 2 - 61 + 12,0Treatment Group III. 2 - 61 + 12.0
Behandlingsgruppe IV. 2 .0,1 - 62+2,1 25 Behandlingsgruppe V. - - 0,1 74+2,3Treatment Group IV. 2 .0.1 - 62 + 2.1. Treatment Group V. - - 0.1 74 + 2.3
Behandlingsgruppe VI. 2 - 0,1 91+3,9 x Hoffmann la RocheTreatment Group VI. 2 - 0.1 91 + 3.9 x Hoffmann la Roche
Signifikans, ntal forsøgsdyr, arrangement samt bestem:-melsesmetode var som angivet under ' 1 d) ovenfor.Significance, number of test animals, arrangement and determination: - method of measurement was as indicated under '1 d) above.
3535
Claims (2)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUFE000928 | 1974-04-29 | ||
HU74FE00000928A HU171576B (en) | 1974-04-29 | 1974-04-29 | Process for the isolation of gamma-l-glutamyl-taurine |
HUCI001558 | 1975-03-26 | ||
HU74CI1558A HU174114B (en) | 1975-03-26 | 1975-03-26 | Process for producing new aminoacid derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
DK442477A DK442477A (en) | 1977-10-06 |
DK155732B true DK155732B (en) | 1989-05-08 |
DK155732C DK155732C (en) | 1989-10-02 |
Family
ID=26318406
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK182875A DK155433C (en) | 1974-04-29 | 1975-04-28 | METHOD OF ANALOGUE FOR THE PREPARATION OF AMINO ACID DERIVATIVES OR PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF |
DK442877A DK158676C (en) | 1974-04-29 | 1977-10-06 | METHOD OF ANALOGUE FOR THE PREPARATION OF POLYMERS OR OLIGOMER AMINO ACID DERIVATIVES OR PHYSIOLOGICALLY ACCEPTABLE SALTS. |
DK442977A DK442977A (en) | 1974-04-29 | 1977-10-06 | GAMMA-L-GLUTAMYLTAURIN PROCEDURE |
DK442577A DK442577A (en) | 1974-04-29 | 1977-10-06 | PROCEDURE FOR THE PREPARATION OF AMINO ACID DERIVATIVES |
DK442377A DK155520C (en) | 1974-04-29 | 1977-10-06 | METHOD OF ANALOGUE FOR THE PREPARATION OF AMINO ACID DERIVATIVES OR PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF |
DK442777A DK442777A (en) | 1974-04-29 | 1977-10-06 | PROCEDURE FOR THE PREPARATION OF AMINO ACID DERIVATIVES |
DK443077A DK159267C (en) | 1974-04-29 | 1977-10-06 | METHOD OF ANALOGUE FOR THE PREPARATION OF TAURIN DERIVATIVES OR HOMOTAURIN DERIVATIVES OR PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF |
DK442677A DK159654C (en) | 1974-04-29 | 1977-10-06 | METHOD OF ANALOGUE FOR THE PREPARATION OF AMINO ACID DERIVATIVES OR PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF |
DK442477A DK155732C (en) | 1974-04-29 | 1977-10-06 | ANALOGY PROCEDURE FOR THE PREPARATION OF AMINO ACID DERIVATIVES |
DK245783A DK155672C (en) | 1974-04-29 | 1983-05-31 | METHOD OF ANALOGUE FOR THE PREPARATION OF AMINO ACID DERIVATIVES OR PHYSIOLOGICALLY ACCEPTABLE SALTS OR OPTICALLY ACTIVE ISOMER THEREOF |
Family Applications Before (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK182875A DK155433C (en) | 1974-04-29 | 1975-04-28 | METHOD OF ANALOGUE FOR THE PREPARATION OF AMINO ACID DERIVATIVES OR PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF |
DK442877A DK158676C (en) | 1974-04-29 | 1977-10-06 | METHOD OF ANALOGUE FOR THE PREPARATION OF POLYMERS OR OLIGOMER AMINO ACID DERIVATIVES OR PHYSIOLOGICALLY ACCEPTABLE SALTS. |
DK442977A DK442977A (en) | 1974-04-29 | 1977-10-06 | GAMMA-L-GLUTAMYLTAURIN PROCEDURE |
DK442577A DK442577A (en) | 1974-04-29 | 1977-10-06 | PROCEDURE FOR THE PREPARATION OF AMINO ACID DERIVATIVES |
DK442377A DK155520C (en) | 1974-04-29 | 1977-10-06 | METHOD OF ANALOGUE FOR THE PREPARATION OF AMINO ACID DERIVATIVES OR PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF |
DK442777A DK442777A (en) | 1974-04-29 | 1977-10-06 | PROCEDURE FOR THE PREPARATION OF AMINO ACID DERIVATIVES |
DK443077A DK159267C (en) | 1974-04-29 | 1977-10-06 | METHOD OF ANALOGUE FOR THE PREPARATION OF TAURIN DERIVATIVES OR HOMOTAURIN DERIVATIVES OR PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF |
DK442677A DK159654C (en) | 1974-04-29 | 1977-10-06 | METHOD OF ANALOGUE FOR THE PREPARATION OF AMINO ACID DERIVATIVES OR PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK245783A DK155672C (en) | 1974-04-29 | 1983-05-31 | METHOD OF ANALOGUE FOR THE PREPARATION OF AMINO ACID DERIVATIVES OR PHYSIOLOGICALLY ACCEPTABLE SALTS OR OPTICALLY ACTIVE ISOMER THEREOF |
Country Status (23)
Country | Link |
---|---|
JP (1) | JPS6012347B2 (en) |
AR (3) | AR218221A1 (en) |
AT (6) | AT361902B (en) |
AU (1) | AU499173B2 (en) |
BE (1) | BE828546A (en) |
BG (4) | BG26370A4 (en) |
CA (1) | CA1051802A (en) |
CH (4) | CH617183A5 (en) |
CS (4) | CS209855B2 (en) |
DD (2) | DD125070A5 (en) |
DE (2) | DE2518160A1 (en) |
DK (10) | DK155433C (en) |
EG (1) | EG11847A (en) |
ES (4) | ES436986A1 (en) |
FI (1) | FI65990C (en) |
FR (1) | FR2279388A1 (en) |
GB (1) | GB1504541A (en) |
IL (1) | IL47149A (en) |
NL (1) | NL183186C (en) |
NO (2) | NO146430C (en) |
PL (2) | PL111745B1 (en) |
SE (2) | SE430164B (en) |
SU (1) | SU747419A3 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU178199B (en) * | 1976-05-06 | 1982-03-28 | Chinoin Gyogyszer Es Vegyeszet | New process for producing amides of omega-amino-carboxylic acids |
HU180443B (en) * | 1979-04-02 | 1983-03-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing a pharmaceutical preparation with synergetic action against radiation |
HU185632B (en) * | 1981-03-27 | 1985-03-28 | Chinoin Gyogyszer Es Vegyeszet | New process for preparing gamma-glutamyl-taurine |
CH665645A5 (en) * | 1981-07-09 | 1988-05-31 | Michel Flork | DIPEPTIDE DERIVATIVES AND THEIR PREPARATION PROCESS. |
HU208072B (en) * | 1990-02-28 | 1993-08-30 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition suitable for preventing and curing autoimmune diseases and skin affections caused by heat and light radiacion |
JPH0680964A (en) * | 1991-12-27 | 1994-03-22 | Sogo Yatsukou Kk | Active-oxygen scavenger |
JPH11180846A (en) * | 1997-12-15 | 1999-07-06 | Sogo Pharmaceut Co Ltd | Cosmetic |
DE10133197A1 (en) * | 2001-07-07 | 2003-01-23 | Beiersdorf Ag | Use of topical compositions containing beta-amino acids, guanidinoethanesulfonate, homotaurine and their precursors and derivatives e.g. to improve skin condition and to treat or prevent skin disorders |
DK2089417T3 (en) | 2006-10-12 | 2015-03-23 | Bhi Ltd Partnership | Methods, Compounds, Compositions and Vehicles for Delivery of 3-Amion-1-Propanesulfonic Acid |
US9662304B1 (en) * | 2013-06-13 | 2017-05-30 | Thermolife International, Llc | Substituted glutaurine compounds and substituted glutaurine derivatives |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU169462B (en) * | 1971-08-04 | 1976-11-28 |
-
1975
- 1975-04-23 IL IL47149A patent/IL47149A/en unknown
- 1975-04-24 DE DE19752518160 patent/DE2518160A1/en active Granted
- 1975-04-24 DE DE2559989A patent/DE2559989C3/en not_active Expired
- 1975-04-24 AT AT314075A patent/AT361902B/en not_active IP Right Cessation
- 1975-04-25 ES ES436986A patent/ES436986A1/en not_active Expired
- 1975-04-25 FI FI751256A patent/FI65990C/en not_active IP Right Cessation
- 1975-04-25 SE SE7504828A patent/SE430164B/en not_active IP Right Cessation
- 1975-04-28 CH CH539075A patent/CH617183A5/de not_active IP Right Cessation
- 1975-04-28 NO NO751504A patent/NO146430C/en unknown
- 1975-04-28 CA CA225,659A patent/CA1051802A/en not_active Expired
- 1975-04-28 SU SU752128794A patent/SU747419A3/en active
- 1975-04-28 EG EG262/75A patent/EG11847A/en active
- 1975-04-28 FR FR7513230A patent/FR2279388A1/en active Granted
- 1975-04-28 AU AU80564/75A patent/AU499173B2/en not_active Expired
- 1975-04-28 DD DD193288A patent/DD125070A5/xx unknown
- 1975-04-28 DD DD185727A patent/DD122377A5/xx unknown
- 1975-04-28 DK DK182875A patent/DK155433C/en not_active IP Right Cessation
- 1975-04-28 GB GB17608/75A patent/GB1504541A/en not_active Expired
- 1975-04-29 BG BG030770A patent/BG26370A4/en unknown
- 1975-04-29 BG BG030768A patent/BG26369A4/en unknown
- 1975-04-29 PL PL1975196801A patent/PL111745B1/en unknown
- 1975-04-29 BG BG030769A patent/BG26517A4/en unknown
- 1975-04-29 NL NLAANVRAGE7505075,A patent/NL183186C/en not_active IP Right Cessation
- 1975-04-29 CS CS752987A patent/CS209855B2/en unknown
- 1975-04-29 BE BE155914A patent/BE828546A/en not_active IP Right Cessation
- 1975-04-29 BG BG029816A patent/BG26368A3/en unknown
- 1975-04-29 PL PL1975196798A patent/PL111746B1/en unknown
- 1975-04-30 JP JP50051612A patent/JPS6012347B2/en not_active Expired
-
1976
- 1976-04-02 AR AR262768A patent/AR218221A1/en active
- 1976-04-02 AR AR262770A patent/AR218222A1/en active
- 1976-04-02 AR AR262769A patent/AR217236A1/en active
- 1976-11-13 ES ES453304A patent/ES453304A1/en not_active Expired
- 1976-11-13 ES ES453306A patent/ES453306A1/en not_active Expired
- 1976-11-13 ES ES453305A patent/ES453305A1/en not_active Expired
-
1977
- 1977-08-30 AT AT624777A patent/AT359084B/en not_active Expired
- 1977-08-30 AT AT624977A patent/AT351007B/en not_active IP Right Cessation
- 1977-08-30 AT AT624877A patent/AT359085B/en not_active IP Right Cessation
- 1977-10-06 DK DK442877A patent/DK158676C/en active
- 1977-10-06 DK DK442977A patent/DK442977A/en unknown
- 1977-10-06 DK DK442577A patent/DK442577A/en not_active Application Discontinuation
- 1977-10-06 DK DK442377A patent/DK155520C/en not_active IP Right Cessation
- 1977-10-06 DK DK442777A patent/DK442777A/en not_active Application Discontinuation
- 1977-10-06 DK DK443077A patent/DK159267C/en not_active IP Right Cessation
- 1977-10-06 DK DK442677A patent/DK159654C/en not_active IP Right Cessation
- 1977-10-06 DK DK442477A patent/DK155732C/en not_active IP Right Cessation
-
1978
- 1978-09-22 CS CS786128A patent/CS209856B2/en unknown
- 1978-09-22 CS CS786130A patent/CS209858B2/en unknown
- 1978-09-22 CS CS786129A patent/CS209857B2/en unknown
- 1978-12-14 SE SE7812884A patent/SE441356B/en not_active IP Right Cessation
-
1979
- 1979-04-30 AT AT0323179A patent/AT370724B/en not_active IP Right Cessation
- 1979-04-30 AT AT0323079A patent/AT374484B/en not_active IP Right Cessation
- 1979-10-19 CH CH943379A patent/CH624098A5/de not_active IP Right Cessation
- 1979-10-19 CH CH943279A patent/CH621334A5/de not_active IP Right Cessation
- 1979-10-19 CH CH943179A patent/CH621333A5/de not_active IP Right Cessation
-
1981
- 1981-03-10 NO NO810816A patent/NO149036C/en unknown
-
1983
- 1983-05-31 DK DK245783A patent/DK155672C/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU747407B2 (en) | Use of organophosphoric compounds for the therapeutic and preventative treatment of infections | |
CZ20004893A3 (en) | Compound similar to N-acyl dipeptide, process of its preparation and pharmaceutical preparation in which it is comprised | |
CA2945404A1 (en) | Bone-selective osteogenic oxysterol bisphosphonate analogs | |
DK155732B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF AMINO ACID DERIVATIVES | |
TW202140034A (en) | Compounds and pharmaceutical uses thereof | |
TWI721697B (en) | Compounds used to treat osteoarthritis | |
JPS6124377B2 (en) | ||
EP0207505A2 (en) | Use of a prenyl ketone in the preparation of a medicament against gastritis | |
NO874241L (en) | THERAPEUTIC ACTIVE SALTS. | |
NL8201320A (en) | ESTER OF MERCAPTO-ACYLCARNITINES, METHOD FOR PREPARING AND PHAMACEUTICAL PREPARATIONS CONTAINING THESE ESTERS. | |
NO146325B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY EFFECTIVE L-CYSTEIN DERIVATIVES | |
Laskar et al. | Influence of teak (Tectona grandis; family: Verbenaceae) seed protein on some enzymes and liver lipids of albino rats | |
FI68243B (en) | FRAMEWORK FOR PHARMACOLOGICAL ACTIVATION OF ACTIVE DIPHOSPHONATERS | |
NO137545B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF BIS (PARA-CHLOROPHENOXY) CARBINOL DERIVATIVES | |
PL106523B1 (en) | METHOD OF MAKING NEW AMINO ACID DERIVATIVES | |
EP0507348A2 (en) | Superoxide dismutase derivatives | |
McKendry | Some Aspects of Choline Metabolism | |
JPH10218767A (en) | Therapeutic agent for bone disease | |
GB2193719A (en) | Antiallergic phenoxypropanol thioether derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PBP | Patent lapsed |